Clinical Trials Browser

Interventional × pomalidomide × Myeloid × Clear all

NCT04802161 2025-12-19

Comparing the Addition of an Anti-Cancer Drug, Pomalidomide, to the Usual Chemotherapy Treatment (Daunorubicin and Cytarabine Liposome) in Newly Diagnosed Acute Myeloid Leukemia With Myelodysplastic Syndrome-Related Changes

Phase 2 Active not recruiting

50 enrolled 12 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT02029950 2020-10-14

Pomalidomide After Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Phase 1 Completed

MyeloidOther hematologic neoplasm

Myeloproliferative Disorders, Leukemia, Myeloid, Acute

NCT00669578 2019-12-30

CC-4047 in Treating Patients With Myelofibrosis

Phase 1/2 Completed

77 enrolled 9 charts

Myeloproliferative Disorders, Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

NCT00463385 2019-11-20

A Phase II Study of Pomalidomide in Myelofibrosis With Myeloid Metaplasia

Phase 2 Completed

88 enrolled 22 charts

MyeloidOther hematologic neoplasm

Leukemia, Megakaryoblastic, Acute, Primary Myelofibrosis

NCT01178281 2019-07-17

RESUME

Phase 3 Completed

267 enrolled 19 charts

Primary Myelofibrosis

NCT01243944 2019-03-06

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Phase 3 Completed

222 enrolled 21 charts

Polycythemia Vera

NCT00949364 2017-09-25

Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage

Phase 2 Completed

Myeloproliferative Disorders